Compare APLE & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APLE | IMNM |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2007 | 2020 |
| Metric | APLE | IMNM |
|---|---|---|
| Price | $15.95 | $18.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $13.00 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 2.3M | 1.1M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,238,622,000.00 | $6,941,000.00 |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | $2.35 | $1,127.34 |
| P/E Ratio | $129.96 | ★ N/A |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $10.85 | $7.96 |
| 52 Week High | $15.81 | $27.65 |
| Indicator | APLE | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 77.51 | 34.39 |
| Support Level | $11.50 | $16.81 |
| Resistance Level | N/A | $19.16 |
| Average True Range (ATR) | 0.33 | 1.23 |
| MACD | 0.07 | -0.32 |
| Stochastic Oscillator | 96.78 | 8.72 |
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.